Want to talk to us about neurotechnology?
Neurotechnology promises to revolutionise the treatment of a wide range of diseases. Improving outcomes for patients depends on bringing together an understanding of the pathology with the medical device hardware needed to physically interface with the nervous system.
The incidence of complex chronic pain disorders and neurological diseases has been rising steadily. Today they affect more than 20% of the population and inflict a financial burden of over $800 billion per year in North America alone. Yet traditional pharmaceutical solutions such as opioids have limitations: many patients experience limited efficacy, and they cause a wide range of unwanted side effects, from drowsiness to long-term addiction.
Neuromodulation therapies can offer a welcome alternative to pharmaceuticals. Spinal cord stimulation has proved to be an effective method to relieve chronic back pain, and deep brain stimulation has enabled many Parkinson’s patients to regain independence and dramatically improved their quality of life. With the advent of advanced sensing technologies, closed-loop stimulation can be tailored to individual patients to maximise therapeutic benefit whilst minimising unwanted side effects. Future advances in technology will allow detection and response to neurological events in real time, and the ability to intervene in a whole spectrum of brain, nerve, autoimmune, and autonomic conditions.
To reach a wider population of patients, there is also a trend towards less invasive neuromodulation devices. This poses the challenge of balancing patient safety and ease of use against selectivity and efficacy. Advances in AI and machine learning techniques are improving the accuracy of non-invasive neural interfaces, and together with improvements in hardware capability a new generation of products is emerging.
TTP uniquely combines longstanding expertise in medical device development, multiphysics modelling, advanced electronics and sensing techniques with recent advances in material science and manufacturing, making us an ideal development partner for companies looking to create innovative neuromodulation technologies and develop devices for the treatment of neurological disorders.
We work at the intersection of physics, engineering and the biological sciences, creating and developing new technology for the life science industry.
Pharmaceutical companies face substantial challenges, from constraints in health spending to weakening drug pipelines. Yet opportunities exist for those bold enough to adapt, ranging from connected devices that drive adherence to generic devices at cost points previously thought impossible.
Disruptive change is rolling through the medical device industry as value-based healthcare and digitisation spread from niches to the mainstream. This is a challenging time, but it presents real opportunities for those ambitious companies prepared to reinvent themselves.
The diagnostic market is at a moment of change. New approaches, such as sequencing, are gaining traction; companion diagnostics are driving closer integration with therapy; continuous monitoring is enabling new diagnostic information; and market drivers are demanding low cost distribution of clinical quality data.
Human therapies are adapting to tackle increasingly complex immunological diseases and conditions. These therapies often rely on tightly controlled cell cultures in order to produce therapeutic drugs efficiently, such as monoclonal antibodies or culture of the patient’s own genetically-engineered cells, as part of an autologous cell therapy workflow.
Emerging biosensor technologies are enabling the measurement and analysis of valuable trace markers, leading to improved clinical outcomes by allowing the accurate observation of previously undetectable physiological signals in real time.
Increasing numbers of people are suffering from chronic conditions. Through the creation of tiny, fully integrated real-time measurement systems, smart implants are bringing the benefits of laboratory-grade telemetry to their lives.
As with other industries, digital technology is touching every aspect of healthcare. But health is unique in its complexity, and innovation requires deep insight.
Medical imaging is required to meet the needs of advanced diagnostics and the demands of emerging markets, presenting the sector with sizeable rewards for innovation.
Surgery is a fertile area for medical device innovation with remarkable developments occurring in minimally invasive and robotic assisted techniques. The future of the operating room relies on intraoperative technologies which improve clinical and economic values as measured by procedure outcome, workflow efficiency and patient safety.
Cell and Gene Therapies can cure the incurable. With more than a decade of experience, TTP works in partnership with companies to solve the challenges of these complex therapies. Together we will improve patient access and save lives.